Background: Combining established therapies with recently discovered immunotherapies is a promising
approach for treating malignant melanoma. Our research group has been studying intratumoral
electrochemotherapy (a combination of a chemotherapeutic drug and electroporation),
which is a well-established therapy in clinics across Europe [1]. Besides local release
or exposition of damage-associated molecular patterns and neoantigens, electrochemotherapy
with cisplatin, oxaliplatin or bleomycin induces immunogenic cell death [2, 3]. Although
local effectiveness of electrochemotherapy is up to 80 % of local tumor control, no
noticeable effects on distant non-treated metastases have been observed [1]. We hypothesized
that gene electrotransfer of plasmid encoding for interleukin-12 (IL-12) as an adjuvant
immunotherapy, compliments the responses seen with electrochemotherapy on a local
and systemic level.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P05.03
Identification
Copyright
© 2018 Published by Elsevier Inc.
